whatshot

NKTX   $5.3953  0.47% Market Open

Nkarta Inc
show_chart Advanced Chart of NKTX
Last Events:

2023-08-05 Trend pattern changed from расширяющаяся формация to нисходящий клин.

2023-08-05 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-04 Trend pattern changed from канал to расширяющаяся формация.

2023-08-04 Signal in Stochastic changed from bullish to bullish weakening. The stochastic indicator is in the upper part of the neutral territory and it heading south. These factors indicate that the downside trend is forming. Last signal: main and signal line crossing.

2023-08-03 Trend pattern changed from расходящийся треугольник to канал.

2023-08-03 Signal in RSI changed from bullish reversal to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-02 Signal in Stochastic changed from bearish to bullish. The stochastic indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: up-crossing the middle level.

2023-07-30 Trend pattern changed from канал to расходящийся треугольник.

Current temperature: 0.00
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 6
Target Price Mean 17.33
Mean unverified/preliminary 17.33 / 17.33
Target Price Low / High 13.00 / 22.00
Median / STD DEV 17.00 / 3.33
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy Buy None
rsi ActivelyBuy Buy ActivelyBuy
macd None ActivelyBuy None
stoch ActivelyBuy None None
ma20 ActivelyBuy None None
ma50 ActivelyBuy None None
ma100 ActivelyBuy Buy Sell
Candlestick PatternSept. 12, 2024 Bearish Belt Hold - is a candlestick that has a long black body and small shadows. It opens on the high of the day. It occurs in a uptrend. Considered to be a bearish reversal pattern.
ISIN US65487U1088
ceo Mr. Paul J. Hastings
Website https://www.nkartatx.com
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.